JLCVX
Price
$78.59
Change
-$0.00 (-0.00%)
Updated
Oct 4 closing price
VSMPX
Price
$255.78
Change
-$2.45 (-0.95%)
Updated
Oct 7 closing price
Ad is loading...

JLCVX vs VSMPX

Header iconJLCVX vs VSMPX Comparison
Open Charts JLCVX vs VSMPXBanner chart's image
JHancock Fundamental Large Cap Core R5
Price$78.59
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Total Stock Mkt Idx Instl Pls
Price$255.78
Change-$2.45 (-0.95%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
JLCVX vs VSMPX Comparison Chart
Loading...
VS
JLCVX vs. VSMPX commentary
Oct 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JLCVX is a Buy and VSMPX is a Buy.

FUNDAMENTALS
Fundamentals
VSMPX has more cash in the bank: 1.75T vs. JLCVX (5.74B). VSMPX pays higher dividends than JLCVX: VSMPX (1.36) vs JLCVX (0.47). JLCVX was incepted earlier than VSMPX: JLCVX (15 years) vs VSMPX (9 years). JLCVX is a more actively managed with annual turnover of: 19.00 vs. VSMPX (2.00). JLCVX has a lower initial minimum investment than VSMPX: JLCVX (0) vs VSMPX (100000000). VSMPX annual gain was more profitable for investors over the last year : 34.54 vs. JLCVX (29.74). VSMPX return over 5 years is better than : 89.60 vs. JLCVX (68.87).
JLCVXVSMPXJLCVX / VSMPX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence15 years9 years-
Gain YTD18.00319.27393%
Front LoadN/AN/A-
Min. Initial Investment0100000000-
Min. Initial Investment IRAN/AN/A-
Net Assets5.74B1.75T0%
Annual Yield % from dividends0.471.3635%
Returns for 1 year29.7434.5486%
Returns for 3 years3.3326.6812%
Returns for 5 years68.8789.6077%
Returns for 10 years102.88N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SNAL1.020.29
+40.32%
Snail
TYRA22.040.46
+2.13%
Tyra Biosciences
MG11.300.19
+1.71%
Mistras Group
GEHC91.421.54
+1.71%
GE HealthCare Technologies
BBIO25.23-0.40
-1.56%
BridgeBio Pharma